Fibrosis represents the culmination of persistent inflammatory responses triggered by various factors such as ongoing infections, autoimmune reactions, chemical exposure, radiation, tissue damage, and notably, cancer. It often leads to significant impairment of organ function, or in the case of bone marrow, compromised blood production, posing a significant threat to life. Once established, fibrosis is irreversible, underscoring the importance of halting its progression at an early stage.
Myelofibrosis (MF) exemplifies an incurable blood cancer characterized by progressive bone marrow fibrosis. The evolution of MF from an initial pre-fibrotic phase to full-fledged fibrosis suggests a gradual process, yet the precise changes in the early phase remain poorly understood, lacking specific diagnostic markers. Notably, there are no targeted anti-fibrotic therapies tailored for blood cancers. Allogeneic stem cell transplant (ASCT) stands as a potentially curative option, albeit high-risk and often inaccessible to the majority of patients, with unpredictable outcomes.
Our project has taken significant strides toward enhancing both the diagnosis and treatment of fibrosis related to blood cancer, culminating in the initiation of a proof-of-concept clinical trial. Through our research, we've made pivotal advancements in understanding the underlying mechanisms driving fibrosis, identifying crucial biomarkers, and pinpointing therapeutic targets. Our efforts have paved the way for more effective diagnostic methods and promising therapeutic interventions tailored specifically for fibrosis associated with blood cancer. This milestone of commencing a proof-of-concept clinical trial underscores the tangible progress we've achieved in translating our findings into actionable solutions for patients.
